



BlueCross BlueShield
of Alabama

Name of Blue Advantage Policy:

Amniotic Membrane Grafts for Ophthalmic Indications

Policy #: 624

Latest Review Date: February 2022

Category: Medical

BACKGROUND:

Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:

1. *Safe and effective;*
2. *Not experimental or investigational*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
 - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
 - *Furnished in a setting appropriate to the patient's medical needs and condition;*
 - *Ordered and furnished by qualified personnel;*
 - *One that meets, but does not exceed, the patient's medical need; and*
 - *At least as beneficial as an existing and available medically appropriate alternative.*

Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

POLICY:

Effective for dates of service on or after June 26, 2019:

Blue Advantage will treat **human amniotic membrane grafts** (with or without suture [e.g. Prokera[®], AmbioDisk[™]], and/or with suture or glue) for the treatment of the following ophthalmic indications as a **covered benefit**:

- Absence of iris;
- Bullous keratopathy;
- Conjunctivochalasis;
- Corneal degeneration;
- Corneal ectasia, corneal staphyloma, descemetocoele or other corneal deformity;
- Corneal ulceration or defect;
- Corneal disorder due to contact lens or recurrent erosion of cornea;
- Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment;
- Following removal of conjunctival lesion(s);
- Hereditary corneal dystrophies;
- Neurotrophic keratoconjunctivitis;
- Ocular burns;
- Stevens-Johnsons Syndrome;
- Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient;
- Persistent Epithelial defects that do not respond to conservative therapy;
- Pterygium;
- Pseudopterygium

Blue Advantage will treat **amniotic membrane transplantation** for the treatment of dry eye syndrome and any other conditions not listed above as a **non-covered benefit**.

Effective for dates of service on and after May 6, 2016 and prior to June 26, 2019:

Blue Advantage will treat **amniotic membrane transplantation for the treatment of corneal conditions refractory to conventional treatment using grafts that are fixated using sutures, glue fixation, secured under a bandage contact lens, self-contained or unfixated (e.g., Prokera[®])** as a **covered benefit** for coverage for the following conditions:

- Absence of iris;
- Bullous keratopathy;
- Conjunctivochalasis;
- Corneal degeneration;

- Corneal ectasia, corneal staphyloma, descemetocele or other corneal deformity;
- Corneal ulceration or defect;
- Corneal disorder due to contact lens or recurrent erosion of cornea;
- Following removal of conjunctival lesion(s);
- Hereditary corneal dystrophies;
- Neurotrophic keratoconjunctivitis;
- Ocular burns;
- Stevens-Johnsons Syndrome;
- Pterygium;
- Pseudopterygium

Blue Advantage will treat **amniotic membrane transplantation** for the treatment of dry eye syndrome and any other conditions **not listed above** as a **non-covered benefit** and as **investigational**.

Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.

DESCRIPTION OF PROCEDURE OR SERVICE:

Several commercially available forms of human amniotic membrane (HAM) are available. Amniotic membrane is being evaluated for the treatment of a variety of ophthalmic conditions. HAM consists of two conjoined layers (the amnion and chorion) to form the innermost lining of the amniotic sac or placenta. When prepared for use as an allograft, the membrane is harvested immediately after birth and is cleaned, sterilized, and cryopreserved. Many products available using amnion, chorion, amniotic fluid, and umbilical cord are being studied for use in the treatment of a variety of ophthalmic conditions. The products are formulated either as patches that can be applied as wound covers, or as suspensions, particulates, or connective tissue extractions, which can be injected or applied topically.

HAM contains collagen, fibronectin, and hyaluronic acid, a combination of growth factors, cytokines, and anti-inflammatory proteins (such as interleukin-1 receptor antagonist). There is evidence that the tissue has anti-inflammatory, antifibroblastic, and antimicrobial properties. HAM is considered nonimmunogenic and has not been observed to cause a substantial immune response. It is believed that these properties are retained in cryopreserved HAM and HAM products, resulting in a readily available tissue with regenerative potential.

The use of a HAM graft fixated by sutures is an established treatment of ophthalmic conditions. HAM products that are inserted like a contact lens have been investigated for the treatment of

corneal and ocular surface disorders. The availability of HAM opens the possibility of regenerative medicine for an array of conditions.

KEY POINTS:

The most recent literature update was performed through January 3, 2022 with interim literature update performed through June 8, 2022.

Summary of Evidence

Sutured HAM transplant has been used for many years for the treatment of ophthalmic conditions. Many of these conditions are rare, leading to difficulty in conducting randomized control trials (RCTs). Of the evidence available, relevant outcomes are symptoms, morbid events, functional outcomes, and quality of life. The rarity, severity, and variability of the ophthalmic condition was taken into consideration while evaluating the evidence. Clinical input was sought to help determine whether the use of HAM graft either without or with suture fixation for several ophthalmic conditions would provide a clinically meaningful improvement in the net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, clinical input was received from two respondents, including one specialty society-level response and one physician-level response identified through specialty societies including physicians with academic medical center affiliations.

Bullous keratopathy as a palliative measure in patients who are not candidates for a curative treatment (e.g., endothelial or penetrating keratoplasty)

For individuals who have bullous keratopathy who are not candidates for curative treatment (e.g., endothelial or penetrating keratoplasty) who receive HAM, the evidence includes an RCT. The RCT found no advantage of sutured HAM over the simpler stromal puncture procedure for the treatment of pain from bullous keratopathy, however, clinical input supported the use of amniotic membrane in individuals with this indication as an alternative to stromal puncture. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Corneal perforation when corneal tissue is not immediately available

For individuals who have corneal perforation when corneal tissue is not immediately available who receive sutured HAM, the evidence is limited. The standard treatment for corneal perforation is corneal transplantation, however, HAM may provide temporary coverage of the severe defect when corneal tissue is not immediately available. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment

For individuals with corneal perforation with active inflammation after corneal transplant requiring adjunctive treatment who receive HAM, the evidence is limited. No comparative evidence was identified for this indication. Clinical input supported the use of HAM in individuals with corneal perforation when there is active inflammation after corneal transplant

requiring adjunctive treatment. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Corneal ulcers and melts that do not respond to initial medical therapy

For individuals who have corneal ulcers and melts that do not respond to initial medical therapy who receive HAM, the evidence includes a systematic review of primarily case series and a non-randomized comparative study. The systematic review showed healing in 97% of patients with an improvement of vision in 53% of eyes. One retrospective comparative study with 22 patients found more rapid and complete epithelialization and more patients with a clinically significant improvement in visual acuity following early treatment with self-retained HAM when compared to historical controls. Corneal ulcers and melts are uncommon and variable and RCTs are not expected. Clinical input supported the use of HAM in individuals with corneal ulcers and melts that do not respond to initial medical therapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Dry eye syndrome

For individuals who have severe dry eye syndrome who receive HAM, the evidence is limited. In the article, ‘Treatment outcomes in the DRY Eye Amniotic Membrane (DREAM) study’, a retrospective chart review was conducted of patients with dry eye syndrome who received HAM with at least three months of follow-up was discussed. The patients included in this study were affected by at least one of the following indications: severe dry eye, punctate keratitis, filamentary keratitis, exposure keratitis, neurotropic keratitis, and corneal epithelial defect. The patients in this study continued to use conventional treatment as per their usual routine. It is theorized that the use of HAM can decrease the need for use of prescription medication to alleviate dry eye syndrome, however, evidence for patients who are able to eliminate the standard of care treatment from their treatment plan is insufficient. In the article, ‘Sutureless Amniotic Membrane ProKera for Ocular Surface Disorders: Short-Term Results’, a retrospective chart review of patients who received HAM for ocular surface disorders was discussed. Some success was seen initially in the treatment of dry eye syndrome, however, recurrence of the primary pathologic condition occurred. Sutured HAM is not typically used for severe dry eye alone, but may be necessary in the face of one or more concomitant diseases discussed in the other sections of this policy. Further, well-designed scientific evidence displaying long term effects and a meaningful change in treatment protocol with elimination of use of current standard of care is needed. The evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome when dry eye disease is not accompanied by another disorder.

Moderate or severe acute ocular chemical burns

For individuals who have moderate or severe acute ocular chemical burns who receive HAM, the evidence includes RCTs and retrospective chart reviews. Evidence includes a total of 197 patients with acute ocular chemical burns who were treated with HAM plus medical therapy or medical therapy alone. Two of the three RCTs did not show a faster rate of epithelial healing, and there was no significant benefit for other outcomes. In the article, Sutureless Amniotic Membrane ProKera for Ocular Surface Disorders: Short-Term Results, a chart review of patients who received HAM reports that treatment is easy to use and reasonably well tolerated, with encouraging results in acute moderate chemical injury. Clinical input supported the use of HAM

individuals with moderate or severe acute ocular chemical burn. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Moderate or severe Stevens - Johnson syndrome

For individuals who have moderate or severe Stevens-Johnson syndrome who receive HAM, the evidence includes an RCT that reported 25 patients (50 eyes) found improved symptoms and function with HAM compared to medical therapy alone. Clinical input supported the use of HAM for this indication. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy

For individuals who have neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy who receive HAM, the evidence includes an RCT of 30 patients that showed no benefit of sutured HAM graft compared to tarsorrhaphy or bandage contact lens. Clinical input supported the use of HAM in individuals with this indication. The evidence is sufficient to determine that the technology results in a clinical meaningful improvement in the net health outcome.

Neuropathic corneal pain

For individuals who suffer neuropathic corneal pain, the evidence includes the article, Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain, which is a retrospective single center medical record review of nine patients that evaluated the efficacy, safety, and tolerability of ProKera for the acute treatment of neuropathic corneal pain. The study concludes that the use of HAM represents a novel and promising therapeutic option for patients with neuropathic corneal pain. Small sample size (ten eyes of nine patients) and reported placebo effect experienced in one patient (“patient #4 reported simultaneous resolution of pain the ProKera® Clear untreated eye”) are limitations of this study. Further studies with larger sample size and long term effects is needed to provide efficacy of this treatment. The evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient

For individuals who have partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient and receive HAM, the evidence is limited. No RCTs were identified. Improvement in visual acuity has been reported for some patients who have received HAM in conjunction with removal of the diseased limbus. Clinical input supported the use of HAM in individuals with this indication. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Persistent epithelial defects and ulceration that do not respond to conservative therapy

For individuals who have persistent epithelial defects that do not respond to conservative therapy who receive HAM, the evidence is limited. No comparative trials were identified on persistent epithelial defects and ulceration. Clinical input for this indication supported the use of HAM.

The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft

For individuals who need pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft who receive HAM the evidence includes a systematic review of RCTs that found conjunctival or limbal autograft is more effective than HAM graft in reducing the rate of pterygium recurrence. However, clinical input supported the use of HAM in individuals with pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Superficial punctate keratitis and filamentary keratitis

Superficial punctate keratitis is a nonspecific finding typically caused by an identifiable ocular condition. Filamentary keratitis is an uncommon condition associated with various kinds of ocular surface diseases or conditions. The causative condition of these findings in a patient may be appropriate for treatment with HAM based on scientific evidence or high quality clinical input that has proven HAM is likely to produce a positive outcome in the net health outcome. These causative conditions/indications are listed in the policy statement of this medical policy. Due to the paucity of well-designed scientific trials and evidence to demonstrate an improvement in net health outcomes in patients with indications not included in our policy statement, such indications are found to have insufficient evidence to determine that the technology results in a meaningful improvement in the net health outcome.

Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Tear Film and Ocular Surface Society

In 2017, the Tear Film and Ocular Surface Society published the Dry Eye Workshop II (DEWS) management and therapy report. The report evaluated the evidence on treatments for dry eye and provided a treatment algorithm for dry eye disease management that includes four steps.

U.S. Preventive Services Task Force Recommendations

Not applicable.

KEY WORDS:

Absence of iris, Amniotic membrane transplantation, AMT, dry eye syndrome, keratopathy, bullous keratopathy, conjunctivochalasis, corneal degeneration, corneal ectasia, corneal staphyloma, descemetocoele, other corneal deformity, corneal ulceration, corneal defect, corneal disorder due to contact lens or recurrent erosion of cornea, conjunctival lesion removal, hereditary corneal dystrophies, neurotrophic keratoconjunctivitis, ocular burns, pterygium, pseudopterygium, Stevens-Johnsons Syndrome, SJS, Prokera, HAM, human amniotic membrane

APPROVED BY GOVERNING BODIES:

The U.S. Food and Drug Administration (FDA) regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Human amniotic membrane products and amniotic fluid products are included in these regulations. In 2017, the FDA published clarification of what is considered minimal manipulation and homologous use for human cells, tissues, and cellular and tissue-based products (HCT/Ps).

HCT/Ps are defined as human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. If an HCT/P does not meet the criteria below and does not qualify for any of the stated exceptions, the HCT/P will be regulated as a drug, device, and/or biological product and applicable regulations and premarket review will be required. An HCT/P is regulated solely under section 361 of the PHS Act and 21 CFR Part 1271 if it meets all of the following criteria:

1. "The HCT/P is minimally manipulated;
2. The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
3. The manufacture of the HCT/P does not involve the combination of the cells or tissues with another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent, provided that the addition of water, crystalloids, or the sterilizing, preserving, or storage agent does not raise new clinical safety concerns with respect to the HCT/P; and
4. Either:
 - The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
 - The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:
 - Is for autologous use;
 - Is for allogeneic use in a first-degree or second-degree blood relative; or
 - Is for reproductive use."

The guidance provides the following specific examples of homologous and non-homologous use for amniotic membrane:

"An amniotic membrane product is applied to the surface of the eye to cover or offer protection from the surrounding environment in ocular repair and reconstruction procedures. This is homologous use because serving as a covering and offering protection from the surrounding environment are basic functions of amniotic membrane."

The FDA noted the intention to exercise enforcement discretion for the next 36 months after publication of the guidance.

In 2003, Prokera™ was cleared for marketing by FDA through the 510(k) process for the ophthalmic conformer that incorporates amniotic membrane (K032104). The FDA determined that this device was substantially equivalent to the Symblypharon Ring. The Prokera™ device is

intended “for use in eyes in which the ocular surface cells have been damaged, or underlying stroma is inflamed and scarred.” The development of Prokera, a commercially available product, was supported in part by the National Institute of Health and the National Eye Institute.

AmnioClip (FORTECH GmbH) is a ring designed to hold the amniotic membrane in the eye without sutures or glue fixation. A mounting device is used to secure the amniotic membrane within the AmnioClip. The AmnioClip currently has CE approval in Europe.

BENEFIT APPLICATION:

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

CURRENT CODING:

CPT Codes:

65778	Placement of amniotic membrane on the ocular surface; without sutures
65779	; single layer, sutured
65780	Ocular surface reconstruction; amniotic membrane transplantation, multiple layers

REFERENCES:

1. Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. *Ocul Surf.* Jul 2004; 2(3): 201-11.
2. Chansanti O, Horatanaruang O. The results of amniotic membrane transplantation for symptomatic bullous keratopathy. *J Med Assoc Thai.* 2005; 88 Suppl 9:557-S62.
3. Cheng AM, Zhao D, Chen R, et al. Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. *Ocul Surf.* Jan 2016; 14(1):56-63.
4. Clare G, Suleman H, Bunce C, et al. Amniotic membrane transplantation for acute ocular burns. *Cochrane Database Syst Rev.* 2012; 9:CD009379.
5. Clearfield E, Muthappan V, Wang X, et al. Conjunctival autograft for pterygium. *Cochrane Database Syst Rev.* Feb 11 2016; 2:CD011349.
6. Eslani M, Baradaran-Rafii A, Cheung AY, et al. Amniotic Membrane Transplantation in Acute Severe Ocular Chemical Injury: A Randomized Clinical Trial. *Am J Ophthalmol.* Mar 2019; 199: 209-215.

7. Food and Drug Administration. 510(k) Summary: ProKera™ Bio-Tissue Inc. (K032104). 2003; https://www.accessdata.fda.gov/cdrh_docs/pdf3/K032104.pdf. Accessed January 10, 2022.
8. Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: A review of 10 consecutive cases. *Ophthalmology*. 2011; 118(5):908-14.
9. IOM (Institute of Medicine). 2011. *Clinical Practice Guidelines We Can Trust*. Washington, DC: The National Academies Press.
10. John T, Tighe S, Sheha H, et al. Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease. *J Ophthalmol*. 2017; 2017: 6404918.
11. Kaufman SC, Jacobs DS, Lee WB, et al. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. *Ophthalmology*. Jan 2013; 120(1):201-208.
12. Kheirhah A, Casas V, Raju VK, et al. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol*. May 2008; 145(5): 787-94.
13. Khokhar S, Natung T, Sony P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. *Cornea*. 2005; 24:654–660.
14. Kim HK, Park HS. Fibrin glue-assisted augmented amniotic membrane transplantation for the treatment of large noninfectious corneal perforations. *Cornea*. 2009; 28(2): 170-76.
15. Liu J, Li L, Li X. Effectiveness of Cryopreserved Amniotic Membrane Transplantation in Corneal Ulceration: A Meta-Analysis. *Cornea*. 2019 Apr; 38(4).
16. McDonald MB, Sheha H, Tighe S, et al. Treatment outcomes in the Dry Eye Amniotic Membrane (DREAM) study. *Clin Ophthalmol*. 2018 Apr 9; 12:677-681.
17. Morkin, M. I. and P. Hamrah. "Efficacy of self-retained cryopreserved amniotic membrane for treatment of neuropathic corneal pain." *Ocul Surf* 2018, 16(1): 132-138.
18. Pachigolla G, Prasher P, Di Pascuale MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens*. 2009; 35(4):172-175
19. Paris Fdos S, Goncalves ED, Campos MS, et al. Amniotic membrane transplantation versus anterior stromal puncture in bullous keratopathy: a comparative study. *Br J Ophthalmol*. Aug 2013; 97(8):980-984.
20. Parolini O, Soncini M, Evangelista M, et al. Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine? *Regen Med*. Mar 2009; 4(2):275-291.
21. Prabhasawat P, Tesavibul N, Prakairungthong N, et al. Efficacy of amniotic membrane patching for acute chemical and thermal ocular burns. *J Med Assoc Thal*. 2007; 90: 319-26.
22. Sharma N, Thenarasun SA, Kaur M, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens - Johnson syndrome: a randomized control trial. *Ophthalmology*. Mar 2016; 123(3):484-491.

23. Shay E, Kheirkhah A, Liang L, et al. Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Surv Ophthalmol.* 2009; 54(6):686-96.
24. Srinivas S, Mavrikakis E, Jenkins C. Amniotic membrane transplantation for painful bullous keratopathy. *Eur J Ophthalmol.* 2007; 17(1):7-10.
25. Suri K, Kosker M, Raber I, et al. Sutureless Amniotic Membrane ProKera for Ocular Surface Disorders. Short-Term Results. *Eye Contact Lens.* 2013;39:341-347
26. Tandon R, Gupta N, Kalaivani M, et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol.* 2011; 95(2): 199-204.
27. Toman J, Michael GM, Wisco OJ, et al. Mohs Defect Repair with Dehydrated Human Amnion/Chorion Membrane. *Facial Plast Surg Aesthet Med.* Jan-Feb 2022; 24(1): 48-53.
28. U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use Guidance for Industry and Food and Drug Administration Staff. 2017
<https://www.regulations.gov/document?D=FDA-2017-D-6146-0003> Accessed January 10, 2022
29. Vlasov A, Sia RK, Ryan DS, et al. Sutureless cryopreserved amniotic membrane graft and wound healing after photorefractive keratectomy. *J Cataract Refract Surg.* Mar 2016; 42(3):435-443.
30. Yin HY, Cheng AMS, Tighe S, et al. Self-retained cryopreserved amniotic membrane for treating severe corneal ulcers: a comparative, retrospective control study. *Sci Rep.* Oct 12 2020; 10(1): 17008.

POLICY HISTORY:

Adopted for Blue Advantage, February 2016

Available for comment March 4 through May 5, 2016

Medical Policy Group, May 2016

Medical Policy Group, July 2016

Medical Policy Group, March 2018

Medical Policy Group, June 2019

Medical Policy Group, March 2020

Medical Policy Group, February 2021

Medical Policy Group, February 2022

Medical Policy Group, June 2022: Updates to Description, References. No change to policy statement.

This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.